fda semaglutide approval The #FDA approved the first oral GLP-1 receptor agonist, (#Wegovy pill), for chronic weight management in adults with obesity or overweight with comorbidities, offering a noninjectable alternative with significant weight loss 🎉Exciting news that Semaglutide is

But here we are in real-time, in real life, at the convergence of pharmaceuticals and medicines and consumer-facing technology

2020 global estimate and projected number of adults through 2035 with an overweight BMI [1]. Obesity is a significant independent risk factor contributing to numerous chronic conditions, including diabetes, hypertension, cardiovascular disease, and obstructive sleep apnea syndrome

The study's authors and a U.S

Feeling weak on semaglutide

Discover the temperature requirements for Ozempic and compounded semaglutide alternatives from PlexusDx

A brief review was conducted to explore current evidence on the interaction between GLP-1RAs and gut microbiotatermed the pharmaco-gut axis. Literature was examined to understand how specific microbial populations affect drug efficacy and insulin sensitivity